Spesolimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), HAS (France) and NICE (England) recommended or restricted spesolimab, while AOTMIT (Poland), DMC (Denmark) and NYE METODER (Norway), among others, did not recommend it.
The record spans 3 years, opening at HAS (France) on 19 Apr 2023 and running to 28 Apr 2026.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 14 of 15 records date from 2023 or later.
Against its own class, spesolimab is an outlier: 55% of its decisive outcomes were positive, where molecules sharing ATC class L04A average 78%.
4 distinct indication wordings are recorded for spesolimab by the agencies that label one in English (AWMSG, NICE and SMC).
HAS (France) was first to assess spesolimab, on 19 Apr 2023; AWMSG (Wales) did not open a file until 8 Apr 2026 — a wide spread of 3 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
4 of the 9 agencies here assessed spesolimab more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for spesolimab.
The full ledger for spesolimab reads 5 not recommended, 5 recommended, 2 no benefit and 2 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 8 Apr 2026 | Treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy | excluded, NICE appraised | source |
| AOTMIT (Poland) | 6 Feb 2026 | programu lekowego „Leczenie chorych z łuszczycą (ICD-10: L40.0, L40.1) | not recommended | source |
| HAS (France) | 8 Oct 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| NICE (England) | 18 Jun 2025 | NICE TA1070 | recommended (optimised) | source |
| SMC (Scotland) | 10 Mar 2025 | For the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy. | not recommended | source |
10 further decisions for spesolimab, across 7 agencies, are not shown here. They include the most recent record on file, 28 Apr 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 15 decisions for spesolimab from 9 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.